Methotrexate Treatment Suppresses Monocytes in Nonresponders to Pneumococcal Conjugate Vaccine in Rheumatoid Arthritis Patients

Table 3

Frequencies of circulating leukocytes in RA patients and HC, after vaccination with PCV13.

Phenotype (% of leukocytes unless otherwise specified)	HC ()	0DMARD ()	MTX ()
Monocytes	6.21 (4.59-8.26)	7.19 (5.58-10.5)	7.86 (3.42-10.9)
CD14^++CD16^- (% of monocytes)	82.9 (78.3-86.2)	88.3 (85.5-90.9)	86.5 (80.1-90.1)
CD14^++CD16^+ (% of monocytes)	2.93 (2.34-3.42)	2.12 (1.08-4.47)	3.26 (1.39-4.99)
CD14^+CD16^++ (% of monocytes)	14.8 (10.8-18.9)	7.99 (6.48-10.9)	10.4 (6.63-13.9)
Granulocytes	58.2 (46.0-73.3)	73.2 (53.6-78.2)	71.0 (60.3-81.0)
Basophils	0.870 (0.595-1.26)	0.960 (0.890-1.38)	1.17 (1.11-1.49)
Eosinophils	2.95 (1.91-4.68)	1.90 (1.66-2.59)	5.73 (2.32-8.17)
Neutrophils	54.0 (41.3-69.5)	70.4 (47.9-75.1)	61.7 (55.8-73.5)
Lymphocytes	30.9 (15.9-37.6)	15.2 (10.4-28.4)	15.4 (9.77-29.0)

Frequencies of circulating monocytes, granulocytes, and lymphocytes analyzed in RA patients on MTX treatment for 6-12 weeks, patients in the 0DMARD group and HC, 6-7 days after administration of PCV13, using flow cytometry. Kruskal-Wallis test and Dunn’s multiple comparisons test were used to calculate level of significance. Data are presented with medians and interquartile ranges. RA: rheumatoid arthritis; HC: healthy control; PCV13: 13-valent pneumococcal conjugate vaccine; 0DMARD: without disease-modifying antirheumatic drug treatment; MTX: methotrexate.